Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Starting Cancer Treatment at a Hospital with an Academic Approach Extends Survival

Starting Cancer Treatment at a Hospital with an Academic Approach Extends Survival

On 15 – 18 October 2017, Japan hosted the 18th World Conference on Lung Cancer. According to a study presented there, non-small cell lung cancer treatment begun at a center providing care from an academic perspective may extend patients’ overall survival.

The study used National Cancer Database records for 1.150.722 patients with non-small cell lung cancer. Patients starting their initial treatment at academic centers (%31.5) and nonacademic centers (%68.5) were divided into 2 groups.

The Study Produced Two Important Findings:

1) Among patients diagnosed between 2004 and 2009, median overall survival was 12.4 months, whereas among those diagnosed between 2010 and 2013, it was 14.8 months.

2) Patients starting treatment at centers providing care from an academic perspective had a lower risk of death; 4-year overall survival was %25 at academic centers and %19 at nonacademic centers.

In conclusion, this large study involving 1 and a half million patients shows that advances in cancer diagnosis and treatment and the experience of the center planning treatment are two factors directly affecting patients’ survival.

Sources

Dholaria B, Ailawadhi S, Soyano AE, et al.
Survival trends among non-small cell lung cancer (NSCLC) patients over a decade: impact of initial therapy at academic centers.
International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer; October 2017; Yokohama, Japan.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Starting Cancer Treatment at a Hospital with an Academic Approach Extends Survival

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy